Seagen targets Daiichi in cancer drug suit
22-10-2020
Seattle Genetics requests arbitration to resolve Daiichi Sankyo dispute
14-11-2019
AstraZeneca and Daiichi Sankyo to develop new cancer treatment
02-04-2019
svetlichniy_igor / Shutterstock.com
American Regent, the US subsidiary of pharmaceutical company Daiichi Sankyo, has taken iron therapy specialist Pharmacosmos to court over an injectable treatment for anaemia.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Daiichi Sankyo, American Regent, Pharmacosmos, patent infringement, Injectafer, Monoferric, anaemia,
